H. Lundbeck A/S has appointed the pharmaceutical veteran Johan Luthman as head of research and development, effective 1 March, to advance its portfolio of treatments for central nervous system disorders. Dr Luthman comes to the Danish company from Eisai Co Lt where he has been head of clinical development. Before this he managed neuroscience and ophthalmology drug development at Merck & Co Inc.
Dr Luthman obtained a degree in dental sciences from Karolinska Institute in 1984. He also holds a PhD in neurobiology and histology.
Lundbeck announced the appointment on 22 January 2019.
Copyright 2019 Evernow Publishing Ltd.